Title: RVX 208.
Abstract: RVX 208 (RVX-208; RVX000222) is a first-in-class novel small molecule in development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and Alzheimer disease. It increases the levels of apolipoprotein A1 and high-density lipoprotein cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review discusses the key development milestones and therapeutic trials of this drug.
Subjects: CORONARY heart disease treatment; ATHEROSCLEROSIS treatment; ALZHEIMER'S disease treatment; RESVERLOGIX Corp.; APOLIPOPROTEIN A; CLINICAL drug trials
Publication: Drugs in R&D, 2011, Vol 11, Issue 2, p207
ISSN: 1174-5886
Publication type: Academic Journal
DOI: 10.2165/11595140-000000000-00000

RVX 208.

CORONARY heart disease treatment; ATHEROSCLEROSIS treatment; ALZHEIMER'S disease treatment; RESVERLOGIX Corp.; APOLIPOPROTEIN A; CLINICAL drug trials